TABLE 2.

Specific phenotypic alterations detected in various cell populations in patients with symptomatic multiple myeloma (MM) and smoldering multiple myeloma (SMM) at diagnosis, as well as SMM cases after induction therapy with nine courses of lenalidomide plus dexamethasone (Len/Dex).

TABLE 2.